In vivo development of resistance to novel β-lactam/β-lactamase inhibitor combinations in KPC-producing Klebsiella pneumoniae infections: a case series
Therapy with novel βL/βLICs or cefiderocol may lead to the selection of resistant mutants in the presence of factors influencing the achievement of PK/PD targets. KPC variants are mainly associated with resistance to ceftazidime/avibactam, and some of them (e.g. KPC-14) may also be associated with reduced susceptibility to aztreonam/avibactam and/or cefiderocol. Loss of function of the OmpK35 and OmpK36 porins appears to play a role in the development of resistance to meropenem/vaborbactam and/or imipenem/relebactam, but other mechanisms may also be involved.
Authors
- Gabriele Bianco (ORCID: https://orcid.org/0000-0002-8180-5075)
- Paolo Gaibani (ORCID: https://orcid.org/0000-0003-3791-8635)
- Matteo Boattini (ORCID: https://orcid.org/0000-0001-6726-2716)
- Cristina Costa (ORCID: https://orcid.org/0000-0002-6549-4553)
- Sara Comini
Institutions
- University of Verona (IT)
- University of Lisbon (PT)
- University of Salento (IT)
- Azienda Ospedaliera Citta' della Salute e della Scienza di Torino (IT)
- Azienda Ospedaliera Universitaria Integrata Verona (IT)
- Department of Public Health (US)
- University of Turin (IT)
Publication Details
- Journal
- European Journal of Clinical Microbiology & Infectious Diseases
- Published
- 2024-10-10
- DOI
- https://doi.org/10.1007/s10096-024-04958-w
- Citations
- 15
- Primary Topic
- Antibiotic Resistance in Bacteria
- Type
- article
- Field-Weighted Citation Impact
- 2.55